this study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemoembolization (deb-tace) and conventional transarterial chemoembolization (c-tace) for treating peculiar anatomical sites of gastric cancer liver metastasis.
of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with deb-tace and 33 with c-tace. the deb-tace group comprised 26 males and 9 females aged 28–75 years (56.8±6.3), and the c-tace group included 19 males and 14 females aged 33–77 (60.2±9.4) years. liver functions of the 2 groups were compared between pre-tace and 1-week and 1-month after tace. computed tomography and magnetic resonance imaging were reexamined at 1, 3, and 6 months after tace, and short-term efficacy was assessed based on modified response evaluation criteria in solid tumors.
one month following deb-tace and c-tace, the number of cases with objective response (or) was 29 cases (29 out of 35 cases, 82.9%) and 20 cases (20 out of 33 cases, 60.6%) and disease control (dc) in the 2 groups was 33 cases (33 out of 35 cases, 94.3%) and 26 cases (26 out of 33 cases, 78.8%) respectively (p=0.041, p=0.031). alanine transaminase (alt) and aspartate transaminase (ast) significantly increased in the deb-tace and c-tace groups 1 week later (p<0.001). there were no serious complications in the 2 groups; incidences of nausea and vomiting were significantly lower, but instances of fever were markedly elevated in the deb-tace group (p=0.023, p=0.016, respectively).
the safety, feasibility, and short-term efficacy of deb-tace and c-tace in the treatment of gastric cancer liver metastasis are clear. deb-tace leads to less incidences of nausea and vomiting but more incidences of fever than c-tace.